Skip to main content

Palisade Bio, Inc.

corporate_fare Company Profile

Palisade Bio, Inc.

PALI·NASDAQ·Life Sciences·CIK 0001357459

PALI Biopharma Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation, once-daily, oral phosphodiesterase-4 ("PDE4") inhibitor prodrugs. These prodrugs are designed for targeted delivery to the terminal ileum and colon. The company's primary clinical product candidate, PALI-2108, is under development to treat patients with inflammatory bowel disease ("IBD"), specifically ulcerative colitis ("UC") and Crohn's disease ("CD"). PALI Biopharma's strategy involves advancing its lead candidate, PALI-2108, towards a Phase 2 clinical study in UC. This study is designed to assess clinical remission response and pharmacodynamic biomarkers over 12 weeks, with an extension phase to evaluate maintenance of remission. The company is also completing early studies in FSCD to further characterize PALI-2108's safety, pharmacology, and potential therapeutic benefits across IBD indications. They leverage their drug development platform infrastructure to identify product candidates targeting inflammatory and fibrotic diseases. Additionally, PALI Biopharma pursues strategic partnerships to expand programs and maximize the worldwide potential of its product candidates and platform, and engages in in-licensing/acquisitions or out-licensing/sales of product candidates. The company is currently advancing clinical trials of PALI-2108 for IBD, including UC and CD. PALI Biopharma employs a precision medicine approach, developing a biomarker-based patient selection method. This approach uses clinical and multiomics data from large patient populations to identify PDE4-related biomarkers correlated with IBD and its severity, which are modified by local PDE4-inhibitor therapy in the colon.

Palisade Bio, Inc. (NASDAQ:PALI) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 16 items for PALI at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-10, rated 8/10. Across its 16 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for PALI spans 10-Q, 8-K, S-3, DEFA14A.

Recent high-impact activity:

  • Palisade Bio Q3 Loss Widens to $14.6M; Material Weakness Persists Despite $113.6M Cash
  • Health Canada Clears Palisade Bio's Phase 2b UC Trial, Expanding Global Reach
  • FDA Clears PALI-2108 for Crohn's Disease, Expanding Phase 2 Program
  • Palisade Bio Advances PALI-2108 to Phase 2, Reports Q2 Results and Sets Timelines for UC and Crohn's Trials
  • FDA Clears PALI-2108 for Phase 2 Ulcerative Colitis Trial, Enrollment Starts H2 2026

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$0
Net Income
-$16.78M
Diluted EPS
-$0.30
Op. Cash Flow
-$10.85M
Operating Income
-$18.06M
Cash & Equivalents
$133.38M
Debt / Equity
0.00×
Shares Outstanding
159.44M sh
Source: 10-K · filed 2026-03-20 · accession 0001357459-26-000004

Short Interest & Short Volume

7.76 days to cover

FINRA reported short interest of 29,290,111 shares in PALI as of the October 30, 2026 settlement, a 7.7% decrease from the prior period — about 7.8 days to cover at its recent average daily volume. On November 20, 2026, 32.1% of PALI volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)29,290,111 shares as of October 30, 2026
Change vs prior period▼ 7.7%
Days to cover7.76 at avg daily volume of 3,775,010
Daily short volume (FINRA facilities)32.1% of 1,754,839 shares on November 20, 2026
5-day average short volume42.1%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with P →
$0.87 +3.58% today
52-week range · as of 2026-11-10 $0.87 – $2.85
Market cap
$150.58M
Volume
3.2M (0.9× avg)
3-mo avg 3.4M
Live data · 2026-11-22 06:30 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed PALI - Latest Insights

PALI
Nov 10, 2026, 4:07 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.12
Real-time Price: $0.870 info
Change: -$0.250 (-22%) info
Market Cap: $150.575M info
PALI
Sep 23, 2026, 8:45 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $1.70
Real-time Price: $0.870 info
Change: -$0.830 (-49%) info
Market Cap: $150.575M info
PALI
Sep 22, 2026, 8:35 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.80
Real-time Price: $0.870 info
Change: -$0.930 (-52%) info
Market Cap: $150.575M info
PALI
Aug 10, 2026, 4:20 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.10
Real-time Price: $0.870 info
Change: -$1.23 (-59%) info
Market Cap: $150.575M info
PALI
Jun 29, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $1.87
Real-time Price: $0.870 info
Change: -$1.00 (-53%) info
Market Cap: $150.575M info
PALI
Jun 11, 2026, 5:23 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.77
Real-time Price: $0.870 info
Change: -$0.9013 (-51%) info
Market Cap: $150.575M info
PALI
May 12, 2026, 5:27 PM EDT
Filing Type: S-3
Importance Score:
9
Price at Filing: $1.92
Real-time Price: $0.870 info
Change: -$1.05 (-55%) info
Market Cap: $150.575M info
PALI
May 12, 2026, 4:14 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.94
Real-time Price: $0.870 info
Change: -$1.07 (-55%) info
Market Cap: $150.575M info
PALI
May 12, 2026, 4:04 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.90
Real-time Price: $0.870 info
Change: -$1.03 (-54%) info
Market Cap: $150.575M info
PALI
May 05, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $2.15
Real-time Price: $0.870 info
Change: -$1.28 (-60%) info
Market Cap: $150.575M info
PALI
Apr 29, 2026, 4:49 PM EDT
Filing Type: DEFA14A
Importance Score:
7
Price at Filing: $1.96
Real-time Price: $0.870 info
Change: -$1.09 (-56%) info
Market Cap: $150.575M info
PALI
Apr 29, 2026, 4:49 PM EDT
Filing Type: DEF 14A
Importance Score:
9
Price at Filing: $1.96
Real-time Price: $0.870 info
Change: -$1.09 (-56%) info
Market Cap: $150.575M info
PALI
Apr 17, 2026, 4:30 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $2.31
Real-time Price: $0.870 info
Change: -$1.44 (-62%) info
Market Cap: $150.575M info
PALI
Apr 02, 2026, 8:34 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.84
Real-time Price: $0.870 info
Change: -$0.970 (-53%) info
Market Cap: $150.575M info
PALI
Mar 30, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.78
Real-time Price: $0.870 info
Change: -$0.910 (-51%) info
Market Cap: $150.575M info
PALI
Mar 20, 2026, 4:22 PM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $1.92
Real-time Price: $0.870 info
Change: -$1.05 (-55%) info
Market Cap: $150.575M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets